DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Recently, DPP-IV inhibitors are used as a novel way to augment the incretin system and one of the newest classes of medications in the treatment of type 2 diabetes mellitus (T2DM). Since the DPP-IV inhibitor was first used, about 5 years have passed in USA. However, there were no major side effects including occurrence of cancers. The main mechanism for DPP-IV inhibitors is due to suppress the function of DPP-IV activity. As it is known that the suppressed DPP-IV activity is a marker for early diagnosis of cancers, the reason of disassociation is not clear.

Activation of receptor for advanced glycation endproduct (AGE) is related to sideration of cancers. Meanwhile, the DPP-IV inhibitors may be related to inhibit the activation of receptor for AGE (RAGE). Therefore, DPP-IV inhibitors may work as a cancer protective agent in diabetes by blocking the AGE-RAGE axis.

However, it is not demonstrated why DPP-IV inhibitors have no side effect of occurrence of cancer via blocking the activation of AGE-RAGE.

The investigators examined effect of DPP-IV inhibitors on frequency of cancers and the underlying mechanism using AGE and RAGE before and 5 years after administration of DPP-IV inhibitors in Japanese patients with T2DM.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nagaoka Red Cross Hospital
• Collaborator: Kurume University
• Treatments: Alogliptin; Sitagliptin Phosphate; Vildagliptin

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus patients with or without cancer

• Patients who have no treatment with DPP-IV inhibitors.

• Outpatients regularly visiting hospital

• Patients 20 years old (gender is disregarded)

Exclusion Criteria:

• Patients with a serious complication in the heart, liver or kidney

• Pregnant or possibly pregnant patients, or lactating patients

• Patients participating in other clinical study.

• Other than the above, patients judged inappropriate as the subjects of this study by the investigator